Dr. Kami Kim serves as director of research at Tampa General Hospital’s Global Emerging Diseases Institute. Dr. Kim is an NIH-funded investigator who leads infectious diseases clinical research efforts at TGH. She served as site principal investigator of COVID-19 clinical trials for 3D swabs, antiviral treatments, monoclonal antibodies, and COVID-19 vaccines. Dr. Kim works closely with the TGH Esoteric laboratory led by Dr. Suzane Silbert to track the emergence of SARS-CoV2 variants. She is also working with the TGH business intelligence group and TGH clinical teams to use big data and artificial intelligence to improve infectious diseases clinical outcomes. Dr. Kim completed her training in internal medicine at Columbia Presbyterian Medical Center (now New York Presbyterian Hospital), infectious diseases training at University of California-San Francisco, and post-doctoral research training at Stanford University School of Medicine. She is a member of the editorial advisory board of the Sanford Guide for Antimicrobial Therapy.
Tampa General Hospital
Address: 1 Tampa General Circle
University of California San Fransisco Fellowship, Infectious Diseases, 1990
New York-Presbyterian University Hospital of Columbia and Cornell Residency, Internal Medicine, 1987
New York-Presbyterian University Hospital of Columbia and Cornell Internship, Internal Medicine, 1985
Columbia University College of Physicians and Surgeons Medical School, MD, 1984